Literature DB >> 24552217

Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.

David C Kem1, Hongliang Li, Carolina Velarde-Miranda, Campbell Liles, Megan Vanderlinde-Wood, Allison Galloway, Muneer Khan, Caitlin Zillner, Alexandria Benbrook, Veitla Rao, Celso E Gomez-Sanchez, Madeleine W Cunningham, Xichun Yu.   

Abstract

CONTEXT: The mechanisms causing excessive aldosterone production and hypertension in primary aldosteronism (PA) are complex and often incompletely recognized. Autoantibodies to the angiotensin AT1 receptor (AT1R) have been reported in some PA patients with an aldosterone-producing adenoma but not with idiopathic adrenal hyperplasia.
OBJECTIVE: We investigated whether these autoantibodies will activate AT1R and thereby potentially contribute to the pathophysiology of PA.
DESIGN: AT1R autoantibody activity in sera and/or IgG purified from 13 biochemically confirmed PA patients was measured using AT1R-transfected cells, and their contractile effects were assayed using perfused rat cremaster arterioles. Aldosterone stimulation was measured in vitro using isolated human adrenal carcinoma (HAC15) adrenal cells. These data were compared with sera obtained from a group of normotensive control subjects who were expected to have negligible AT1R autoantibodies.
RESULTS: Sera from each of the 13 PA patients significantly increased AT1R activation in AT1R-transfected cells compared with 20 control subjects, and this activity was inhibited by the selective AT1R blocker losartan. Sera and IgG purified from AT1R autoantibody-positive sera demonstrated significant vasoconstrictive effects in isolated rat cremaster arterioles and were blocked by losartan. Moreover, the AT1R autoantibody-positive IgG directly stimulated aldosterone production in the cultured adrenal cells and enhanced angiotensin-induced aldosterone production in these cells, and these effects were blocked by candesartan.
CONCLUSIONS: These data support a probable pathophysiological role for AT1R autoantibodies in PA and thereby raise important etiological and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24552217      PMCID: PMC4010696          DOI: 10.1210/jc.2013-3282

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension.

Authors:  M L Fu; H Herlitz; W Schulze; G Wallukat; P Micke; P Eftekhari; K G Sjögren; A Hjalmarson; W Müller-Esterl; J Hoebeke
Journal:  J Hypertens       Date:  2000-07       Impact factor: 4.844

2.  Primary aldosteronism: diagnosis, localization, and treatment.

Authors:  M H Weinberger; C E Grim; J W Hollifield; D C Kem; A Ganguly; N J Kramer; H Y Yune; H Wellman; J P Donohue
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

3.  Pseudo-primary aldosteronism. An entity distinct from true primary aldosteronism.

Authors:  L Baer; S C Sommers; L R Krakoff; M A Newton; J H Laragh
Journal:  Circ Res       Date:  1970-07       Impact factor: 17.367

4.  Saline suppression of plasma aldosterone in hypertension.

Authors:  D C Kem; M H Weinberger; D M Mayes; C A Nugent
Journal:  Arch Intern Med       Date:  1971-09

5.  The intercurrent hypertension of primary aldosteronism.

Authors:  E G Biglieri; M Schambelan; P E Slaton; J R Stockigt
Journal:  Circ Res       Date:  1970-07       Impact factor: 17.367

6.  Results of adrenal surgery in patients with hypertension, aldosterone excess, and low plasma renin concentration.

Authors:  J B Ferriss; J J Brown; R Fraser; E Haywood; D L Davies; A W Kay; A F Lever; J I Robertson; K Owen; W S Peart
Journal:  Br Med J       Date:  1975-01-18

7.  Primary aldosteronism with suppressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia.

Authors:  F H Katz
Journal:  Ann Intern Med       Date:  1967-11       Impact factor: 25.391

8.  Primary aldosteronism: factors associated with normalization of blood pressure after surgery.

Authors:  A M Sawka; W F Young; G B Thompson; C S Grant; D R Farley; C Leibson; J A van Heerden
Journal:  Ann Intern Med       Date:  2001-08-21       Impact factor: 25.391

9.  Pathology of the adrenal gland in refractory low-renin hypertension.

Authors:  D L Longo; J A Esterly; C E Grim; W F Keitzer
Journal:  Arch Pathol Lab Med       Date:  1978-06       Impact factor: 5.534

10.  Autoimmune basis for postural tachycardia syndrome.

Authors:  Hongliang Li; Xichun Yu; Campbell Liles; Muneer Khan; Megan Vanderlinde-Wood; Allison Galloway; Caitlin Zillner; Alexandria Benbrook; Sean Reim; Daniel Collier; Michael A Hill; Satish R Raj; Luis E Okamoto; Madeleine W Cunningham; Christopher E Aston; David C Kem
Journal:  J Am Heart Assoc       Date:  2014-02-26       Impact factor: 5.501

View more
  18 in total

Review 1.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

2.  Is postural tachycardia syndrome an autoimmune disorder? And other updates on recent autonomic research.

Authors:  Mitchell G Miglis; Srikanth Muppidi
Journal:  Clin Auton Res       Date:  2020-01-14       Impact factor: 4.435

3.  Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism.

Authors:  Hongliang Li; Xichun Yu; Maria Verena Cicala; Franco Mantero; Alexandria Benbrook; Vineet Veitla; Madeleine W Cunningham; David C Kem
Journal:  J Am Soc Hypertens       Date:  2014-10-23

4.  Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbit.

Authors:  Hongliang Li; David C Kem; Ling Zhang; Bing Huang; Campbell Liles; Alexandria Benbrook; Hariprasad Gali; Vineet Veitla; Benjamin J Scherlag; Madeleine W Cunningham; Xichun Yu
Journal:  Hypertension       Date:  2015-02-17       Impact factor: 10.190

Review 5.  Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: Relevance and pathogenicity.

Authors:  Mary Carmelle Philogene; Tory Johnson; Arthur Jason Vaught; Sammy Zakaria; Neal Fedarko
Journal:  Hum Immunol       Date:  2019-04-19       Impact factor: 2.850

Review 6.  Primary aldosteronism in pregnancy.

Authors:  Vittorio Forestiero; Elisa Sconfienza; Paolo Mulatero; Silvia Monticone
Journal:  Rev Endocr Metab Disord       Date:  2022-05-10       Impact factor: 9.306

7.  AT2R autoantibodies block angiotensin II and AT1R autoantibody-induced vasoconstriction.

Authors:  Campbell Liles; Hongliang Li; Vineet Veitla; Jonathan T Liles; Taylor A Murphy; Madeleine W Cunningham; Xichun Yu; David C Kem
Journal:  Hypertension       Date:  2015-08-10       Impact factor: 10.190

Review 8.  The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications.

Authors:  Teresa M Seccia; Brasilina Caroccia; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez; Gian Paolo Rossi
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

9.  Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role.

Authors:  Chiara Sabbadin; Filippo Ceccato; Eugenio Ragazzi; Marco Boscaro; Corrado Betterle; Decio Armanini
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-07-29       Impact factor: 3.738

10.  Prevalence of Angiotensin II Type 1 Receptor Antibodies in Persons With Hypertension and Relation to Blood Pressure and Medication.

Authors:  Mary Carmelle Philogene; Dingfen Han; Flor Alvarado; Neal S Fedarko; Alan B Zonderman; Michele K Evans; Deidra C Crews
Journal:  Am J Hypertens       Date:  2020-08-04       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.